Reference Detail

Ref Type

Journal Article

PMID

(33419778)

Authors

Malek S, Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D, Xu S, Wang S, Kaminski MS, Devata S, Phillips T

Title

Follicular lymphoma-associated BTK mutations are inactivating resulting in augmented AKT activation.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Clinical cancer research : an official journal of the American Association for Cancer Research			2021 Jan 08	2301-2313	Clin Cancer Res

URL

Abstract Text

Based on the recent discovery of mutations in Bruton's tyrosine kinase (BTK) in Follicular Lymphoma (FL), we studied their functional properties.We identified novel somatic BTK mutations in 7% of a combined total of 139 FL and 11 transformed FL cases, none of which had received prior treatment with B cell receptor (BCR) targeted drugs. We reconstituted WT and mutant BTK into various engineered lymphoma cell lines. We measured BCR-induced signal transduction events in engineered cell lines and primary human FL B cells.We uncovered that all BTK mutants destabilized the BTK protein and some created BTK kinase-dead mutants. The PLCγ2 is a substrate of BTK but the BTK mutants did not alter PLCγ2 phosphorylation. Instead, we discovered that BTK mutants induced an exaggerated AKT phosphorylation phenotype in anti-immunoglobulin (IG) treated recombinant lymphoma cell lines. The shRNA-mediated knock-down of BTK expression in primary human non-malignant lymph node-derived B cells resulted in strong anti-IG-induced AKT activation, as did the degradation of BTK protein in cells lines using ibrutinib-based proteolysis targeting chimera (PROTAC). Finally, through analyses of primary human FL B cells carrying WT or mutant BTK, we detected elevated AKT phosphorylation following surface IG crosslinking in all FL B cells, including all BTK mutant FL. The augmented AKT phosphorylation following BCR crosslinking could be abrogated by pre-treatment with a PI3Kδ inhibitor.Altogether, our data uncover novel unexpected properties of FL-associated BTK mutations with direct implications for targeted therapy development in FL.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References